

International Biotechnology Symposium Explores the Business of Biotech

August 14, 2018 (MONTREAL) - As part of the [18th International Biotechnology Symposium \(IBS 2018\)](#) in Montreal, BIOTECCanada will be moderating a panel during the Business Program exploring how investment capital is key to drive biotech innovation forward to commercialization.

“The Canadian biotech ecosystem is an economic strength that positions Canada well to successfully deliver innovation to a world looking for solutions,” commented Andrew Casey, President and CEO BIOTECCanada. “Biotechnology is built on a transformative idea and its supporting science. Biotechnology commercialization requires many partners and investors along the way. The panel will explore various perspectives from company, incubator and investor. Discussing what it takes to attract specialized investors to commercialize biotech therapies for the global audience.”

Panel Details:

Wednesday August 15, 2018

10:30 a.m. - 12:00 p.m. in room 513 AB

The How's and Why's of Commercializing Canadian Innovation for a Global Market

Moderator: Andrew Casey, President and Chief Executive Officer, BIOTECCanada

Panelists: Anthony Cheung, Chief Technology Officer, enGene

enGene, located at NEOMED, has established strategic alliances with two leading pharmaceutical companies. Together with their corporate partners, they are jointly developing novel therapies for gastrointestinal diseases using the innovative Gene Pill™ platform. These partnerships provide the company access to world-class drug development expertise and near-term financial income that support and accelerate the development of enGene's other wholly-owned programs. enGene is supported by a group of renowned life science-focused investors, including Lumira Ventures, Forbion Capital Partners, Fonds de solidarité FTQ, Pharmstandard Ventures and JJDC, Inc of Johnson & Johnson Innovation. Learn more www.engageinc.com

Donald Olds, President and Chief Executive Officer, NEOMED

With a current occupancy rate approaching 100%, the *NEOMED Innovation Center* has announced a new 100,000 square foot expansion project at the Ville St. Laurent Technoparc site. This new project, will deliver turn-key chemistry, biology and life sciences office space in the Fall of 2019. The first 50,000 square feet phase of this two-phase project will be built adjacent to NEOMED's existing facility in Ville St. Laurent and will be connected to the existing building by a covered walkway, allowing their new tenants easy access to the shared services, cafeteria and meeting rooms. Learn more www.neomed.ca

Steve Xanthoudakis, Chief Business Officer, CQDM

Since its inception in 2008, CQDM, a non-profit biopharmaceutical research consortium and an industrial research cluster, has been driven by the mission to fund projects which accelerate the development of drugs. It does so in conjunction with its partners in the pharmaceutical industry, the same companies which contributed to its creation. CQDM is a catalyst where academia, governments and the life sciences industry converge to create practical solutions to complex medical challenges. Learn more www.cqdm.org

Elizabeth Douville, Founder and Managing Partner, AmorChem

With committed capital of \$41.25M, AmorChem is focused on investing in promising life science projects originating from Québec-based universities and research centres. AmorChem's innovative business model involves financing research-stage projects to enable them to reach pre-clinical proof-of-concept in a semi-virtual mode. AmorChem will generate returns through a two-pronged exit strategy: sell projects having reached

early proof-of-concept to large biotechnology or pharmaceutical companies; or, bundle similar projects into new spin-out companies. Learn more www.amorchem.com

For more information
Nadine Lunt
BIOTECanada
613-230-5585 x257

